Probiotic treatment for depression in adolescents
Probiotic Administration for Adolescent Depression
This study is testing if a probiotic called Visbiome can help improve depression in teenagers and young adults by looking at changes in their brain and gut health.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 77 (estimated) |
| Ages | 15 Years to 24 Years |
| Sex | All |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (San Francisco, California) |
| Trial ID | NCT06898788 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of the probiotic Visbiome on the brain and gut microbiome in adolescents aged 15 to 24 diagnosed with depression. Participants will be randomly assigned to receive either Visbiome or a placebo for eight weeks, with follow-up assessments conducted every two weeks via Zoom or in person. The study aims to evaluate changes in neural connectivity and gut microbiome composition, using functional MRI and stool samples, while also monitoring the safety and tolerability of the treatment.
Who should consider this trial
Good fit: Ideal candidates are adolescents aged 15 to 24 with a primary diagnosis of a depressive disorder and currently on an SSRI.
Not a fit: Patients with other primary DSM-5 mental health disorders or those not currently on an SSRI may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a novel approach to managing depression in adolescents by targeting gut health.
How similar studies have performed: Other studies have shown promising results with probiotics in mental health, but this specific approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female and male participants 15 to 24 years of age * Fluency in English * Access to smartphone, tablet, or computer, on which program "Zoom" can be run for remote visits * Diagnosed with a primary DSM-5 clinical depressive disorder (Major Depressive Disorder, Persistent Depressive Disorder, or Other Specified Depressive Disorder). The DSM-5 clinical depressive disorder will be confirmed by the Schedule for Affective Disorders and Schizophrenia for School-Aged Children-Computerized Version (K-SADS-COMP)47 to participants \<18 years and the Structured Clinic Interview for DSM-5 (SCID-V) to participants ≥18 years. * Participants must be under the care of a primary care clinician and/or mental health professional * Currently on SSRI for at least 8 weeks * BDI-II score greater than 13 Exclusion Criteria: * Current diagnosis of other DSM-5 mental health disorders except for anxiety disorders and ADHD as long as depressive disorder is the primary diagnosis * Current medically-treated with stimulant medication for ADHD unless subject is on stable dosage of stimulant medication and there are no plans to change the stimulant medication or dosage for at least 8 weeks. * Current diagnosis of any Axis II personality disorder(s) as assessed by the K-SADS-COMP or SCID-V. * Oral probiotic use 1 month prior to phone screening * Oral or IV antibiotic use 1 month prior to phone screening * Fermented foods (e.g., yogurt, kombucha) 1 month prior to phone screening * Oral antioxidant or omega 3 supplements \<6 weeks prior to phone screening * Current alcohol intake greater than 2 drinks per week * Smoking cigarettes (\>5 during last 6 months) or tobacco (pipe or hookah #1 time during last month) * Any plans to make significant change in diet and lifestyle * Immunocompromised patients * Allergies to milk, soy, or yeast * Tanner Stage \<3 * Current active suicidal ideation that requires psychiatric hospitalization or suicidal ideation with plan or intent to attempt suicide as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) * Prior suicide attempt within past 6 months that required hospitalization and/or visit to the Emergency Department * History of failure to clinically respond to 2 or more adequate trials of 2 different first-line SSRI antidepressant medications * Any contraindication to MRI (e.g., braces) * Pregnancy or any plans to become pregnant during the study is an exclusion criterion for entrance into the study. Women of reproductive capability will be asked about pregnancy or plans to become pregnant. Women of reproductive capability will be asked to employ at least one of the following allowable contraception methods until they complete their second MRI: birth control implant, birth control shot, birth control patch, birth control pill, condom, internal condom, birth control sponge, cervical cap, spermicide, fertility awareness (calendar method), outercourse and abstinence.
Where this trial is running
San Francisco, California
- UCSF — San Francisco, California, United States (Recruiting)
Study contacts
- Principal investigator: Cherry Leung, PhD, RN — University of California, San Francisco
- Study coordinator: Cherry Leung, PhD, RN
- Email: cherry.leung@ucsf.edu
- Phone: (415) 502-0955
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.